LONDON, June 21 (Reuters) - Shire Plc said on Thursday the U.S. Food and Drug Administration (FDA) intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit ...

LONDON, July 28 (Reuters) - U.S. regulators have delayed approval of Shire's new extended-release hyperactivity drug Intuniv but the British company still expects it to be launched in the United ...

A new study has found a staggering rise in the number of ADHD medication errors among US youth over the last 22 years, most of which occurred at home. The researchers say their findings highlight the ...

Attention deficit hyperactivity disorder, or ADHD, is a common neurodevelopmental disorder that can affect children and adults. It’s often diagnosed during childhood or adolescence — in fact, an ...